FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year. In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, ...
LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
The Zenflow Spring Implant offers a reversible, durable BPH treatment, preserving natural anatomy with a spring-like implant. The BREEZE study showed a 60% responder rate and 37% IPSS improvement, ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
The Revi System, an implantable tibial neuromodulation device, received FDA 510(k) clearance for its enhanced version, improving urgency urinary incontinence treatment. The OASIS trial confirmed the ...
Nogapendekin alfa inbakicept combined with BCG shows promise for BCG-unresponsive NMIBC CIS, with a 71% complete response rate in a single-arm trial. The European Medicines Agency's conditional ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
"The addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival without adversely affecting patient-reported outcomes,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback